PROVEN RESULTS IN DELAYING DISABILITY PROGRESSION
In a 3-year clinical study, MAYZENT® was proven to significantly delay
disability progression
in
people with
relapsing multiple sclerosis (RMS)
. Disability progression was measured by assessing
3-month
confirmed disability progression (CDP)
with the
Expanded Disability Status Scale (EDSS)
Take a look at the results below.
MAYZENT is the first and only pill proven to delay disability
progression, specifically studied in people with more progressed RMS.
OVERALL CLINICAL STUDY RESULTS FOR 3-MONTH CONFIRMED DISABILITY PROGRESSION

showed no confirmed
disability progression*

lower chance of overall
disability progression†
†Compared to those taking placebo.
The effect of MAYZENT was significant in people who had a relapse in the 2 years before the
clinical study
, but not considered significant in people who had not.
ADDITIONAL RESULTS FROM THE MAYZENT CLINICAL STUDY

No significant
difference between
MAYZENT and
placebo
in a timed
25-foot walk test
The timed 25-foot walk test measures how quickly someone can walk 25 feet.
The score is the average of two of these tests.
The timed 25-foot walk test measures how quickly someone can walk 25 feet.
The score is the average of two of these tests.
Because there was no significant difference in the walk test results, it can’t be determined by this study whether the following results were due to treatment with MAYZENT or if they happened by chance.

reduction in annual relapse
rate (ARR)‡
in people on MAYZENT vs placebo

reduction in new or enlarging
t2 lesions.
The mean§ number of lesions was 0.70 for
people on MAYZENT vs 3.60 for placebo

reduction in brain volume loss
(bvl)
in people on MAYZENT vs placebo
Brains typically lose volume as all people age. But in people with MS, tissue damage from inflammation and nerve damage can increase the rate at which people lose brain volume.‖
‖The change for those taking MAYZENT was 0.50% and 0.65% for those taking placebo.

“Every bit of improvement counts. I’ve noticed that MAYZENT
helps me to delay disability progression, and that gives me hope.”
BECKY E.,
A MAYZENT Mentor

Individual results may vary.
THE MAYZENT CLINICAL
STUDY WAS THE LARGEST
STUDY EVER OF PEOPLE
WITH PROGRESSING RMS
In this study, MAYZENT was found to be the first and only pill proven to delay disability progression in people with ore progressed RMS. All 1651 participants with progressing RMS had confirmed disability progression, with or without relapses, in the 2 years leading up to the study.
See below for some important characteristics. MAYZENT may help you stay ahead of disability progression, just like it did for people in the study.

WHERE DO YOU FIT IN?
Fill out the fields below to see how you compare with people in the study.
How many years have you been diagnosed with MS?
How old are you?
Have you been on treatment before?
or
Do you currently, or have you ever, used a walking aid?
or
MRI=magnetic resonance imaging; MS=multiple sclerosis.
$0 CO-PAY OFFER
The Alongside™ MAYZENT support program will help navigate financial options, including $0 co-pay. See if you’re eligible.
STAY INFORMED, STAY AHEAD
Interested in starting MAYZENT? To help decide if it’s right for you, sign up to get information on RMS, tracking progression, MAYZENT effectiveness, and more.